The oncology molecular diagnostics refers to procedure for diagnosing cancers and related services. Molecular diagnostics are tests that diagnose genetic information, proteins, or related molecules and provide health or disease information. The main products in oncology molecular diagnostics are instruments, reagents, and others. The oncology molecular diagnostics instruments are used for diagnosing cancer.. The various technologies involved are polymerase chain reaction (PCR), in-situ hybridization (ISH), isothermic nucleic acid amplification technology (INNAT), chips and microarrays, sequencing, mass spectroscopy, transcription-mediated amplification (TMA), and others. These are used by variousend-users,s such as hospitals, diagnostic centres, academic and research institutes, and others. The oncology molecular diagnostics market research report is one of a series of new reports from The Business Research Company that provides oncology molecular diagnostics market statistics, including oncology molecular diagnostics industry global market size, regional shares, competitors with a oncology molecular diagnostics market share, detailed oncology molecular diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the oncology molecular diagnostics industry. This oncology molecular diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global oncology molecular diagnostics market grew from $3.66 billion in 2022 to $4.19 billion in 2023 at a compound annual growth rate (CAGR) of 14.4%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The oncology molecular diagnostics market is expected to grow from $7.11 billion in 2027 at a CAGR of 14.2%. The rise in the number of cancer cases across the globe is likely to contribute to the growth of the oncology molecular diagnostics market. According to the American Cancer Society, there were 1.8 million new cases and 0.6 million cancer deaths in 2021 in the USA. The four most common types of cancers worldwide are lung, prostate, bowel, and female breast cancer, accounting for 43% of all new cancer cases. Therefore, the rise in cancer incidence rate globally is anticipated to boost the demand for the oncology molecular diagnostic market over the coming years. The high cost of molecular diagnostic tests is a key factor hampering the growth of the oncology molecular diagnostics market. The cost of molecular diagnostic testing is comparatively higher in cancer care and it also depends on the type of therapy. For example, the cost of the molecular diagnostic test for non-small cell lung cancer monotherapy costs about $10,000 to $20,000 per month, and these costs are expected to increase in combination therapy. Therefore, the high cost of molecular diagnostic tests is expected to hamper the growth of the oncology molecular diagnostics market. The advanced technology in genomics is a key trend in the oncology molecular diagnostics market. Advancements in cancer genome sequencing technology, computational analysis, tumor models, and innovation of modern cancer research methods promote early detection of cancer and its mutation. For instance, Roche Molecular Systems, Inc., a US-based company, developed Cobas EGFR Mutation Test for non-small cell lung cancer patients. This test is a real-time test that detects 42 mutations of the epidermal growth factor receptor (EGFR) gene, along with the resistant mutation of cancer. In June 2020, FDA approved Cobas EGFR Mutation Test. In HealthCare Global Enterprises Limited, an India-based oncology care provider acquired Oncology hospital labs and clinical trial business from Strand Lifesciences. The acquisition HCG would enhance its in-house diagnostic and research capabilities and drive higher awareness and adoption of cancer diagnostics. Strand Lifesciences is a India-based oncology and technology company. Major players in the oncology molecular diagnostics market are Abbott Diagnostics, Becton Dickinson, Cepheid, Danaher Corporation, Beckman Coulter, Leica Biosystems, Gen-Probe (Hologic), Qiagen N.V., Roche Diagnostics, and Siemens Healthcare. North America was the largest region in the oncology molecular diagnostics market in 2022. Western Europe was the second largest region in the global oncology molecular diagnostics market report. The regions covered in the global oncology molecular diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the oncology molecular diagnostics market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The oncology molecular diagnostics market includes revenues earned by oncology molecular diagnostics tools and kits. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products. The global oncology molecular diagnostics market is segmented - 1) By Product: Instruments, Reagents, Other Products 2) By Technology: Polymerase Chain Reaction (PCR), In-situ Hybridization (ISH), Isothermic Nucleic Acid Amplification Technology (INNAT), Chips & Microarrays, Sequencing, Mass Spectroscopy, Transcription Mediated Amplification (TMA), Other Technologies 3) By End User: Hospitals, Diagnostic Centers, Academic & Research Institutes, Other End Users

Oncology biosimilars refer to biologically similar drugs or medications that are physiologically comparable to biologic cancer treatments. Infection risk is increased by decreased white blood cell counts, which can be treated as a side effect of cancer therapy. The main drug types of oncology biosimilars are monoclonal antibodies, immunomodulators, hematopoietic agents, and granulocyte colony-stimulating factor (G-CSF). Immunomodulators are a class of drugs that primarily target pathways involved in the treatment of multiple myeloma and a few other cancers. The types of cancer treated include breast cancer, colorectal cancer, blood cancer, neutropenia cancer, and non-small cell lung cancer, and the various distribution channels involved are hospital pharmacies, retail pharmacies, and online pharmacies. The oncology biosimilars market research report is one of a series of new reports from The Business Research Company that provides oncology biosimilars market statistics, including oncology biosimilars industry global market size, regional shares, competitors with an oncology biosimilars market share, detailed oncology biosimilars market segments, market trends and opportunities, and any further data you may need to thrive in the oncology biosimilars industry. This oncology biosimilars market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global oncology biosimilars market grew from $4.19 billion in 2022 to $5.38 billion in 2023 at a compound annual growth rate (CAGR) of 28.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The oncology biosimilars market is expected to grow from $12.83 billion in 2027 at a CAGR of 24.3%. The expiration of the patent of biologics used for the treatment of cancer is driving the production of new oncology biosimilars. Biologics can be patented for a limited period and the expiration of patents for biologics allows the development of new biosimilars. Biologics are targeted drugs synthesized from living organisms that induce the immune system to attack cancer cells. Biosimilars are similar to biologics but are not identical and offer the same effectiveness as biologics at a reduced cost. According to the Center for Biosimilars, patents on nearly 20 oncology biologics will expire by 2023, leading to the development of new biosimilars in cancer care. The increased number of patent expiry is expected to boost the demand for the production of new oncology biosimilars, thus, driving the market growth for oncology biosimilars. The lack of awareness of biosimilars among primary care physicians (PCPs) and specialists limits the growth of the oncology biosimilars market. Biosimilars are manufactured from cell lines and offer the same effectiveness as biologics. However, a lack of detailed awareness of the biosimilars amongst the prescribers reduces the prescriptions of biosimilars affecting the biosimilar market. For instance, as reported by the Health Research Institute of PricewaterhouseCoopers, out of 442 clinicians surveyed 55% of clinicians were unfamiliar with biosimilars and 35% were reluctant to prescribe them due to concerns including the safety of the follow-on biologic. Thus, the lack of awareness about biosimilars among primary care physicians (PCPs) and specialists restricts the growth of the oncology biosimilars market. The pharmaceutical companies are increasingly investing in research and development to produce new oncology biosimilars. The companies are exploiting the growth potential of the rising biosimilar market by investing in their research and development (R&D) processes to support the research and production process of new biosimilars. For instance, in February 2021, Coherus and Junshi Biosciences announced a collaboration in which Coherus would in-license toripalimab, an anti-PD-1 antibody in the US and Canada. Coherus plan to build a leading immuno-oncology franchise using cash from its commercial biosimilar business. Also, in 2019, Biocon, India’s largest biotechnology company invested to acquire some assets of Pfizer Healthcare to set up an R&D facility to boost biosimilar development. Major players in the oncology biosimilars market are Bitcoin, Celltrion Inc., Dr. Reddy's Laboratories Ltd., Intas Pharmaceuticals Ltd., STADA Arzneimittel AG, Pfizer Inc., Apotex Inc., Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, BIOCAD, Amgen, Hospira, F Hoffmann-La Roche, Baxter, Sanofi, Mylan, and F Hoffmann-La Roche. North America was the largest region in the global oncology biosimilars market in 2022. The Middle East is expected to be the fastest-growing region in the forecast period. The regions covered in the global oncology biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the oncology biosimilars market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The oncology biosimilars market consists of sales of Ogivri, Herzuma, Ontruzant, and Trazimera. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products. The global oncology biosimilars market is segmented - 1) By Drug Type: Monoclonal Antibodies, Immunomodulators, Hematopoietic Agents, Granulocyte Colony-Stimulating Factor (G-CSF) 2) By Cancer Type: Breast Cancer, Colorectal Cancer, Blood Cancer, Neutropenia Cancer, Non-Small Cell Lung Cancer, Other Cancer Types 3) By Distribution Type: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Immuno-oncology drugs refer to a therapy or cancer treatment that employs drugs to either boost or suppress the immune system in order to aid the body's defences against cancer, infection, and other disorders. It makes use of chemicals produced by the body or in a lab to strengthen the immune system and assist the body in locating and eliminating cancer cells. The main types of immuno-oncology drugs are monoclonal antibodies, immune checkpoint inhibitors, immune system modulators, cancer vaccines, and others. Monoclonal antibodies are created by cloning a single white blood cell. Every subsequent antibody generated in this manner may be traced back to a single parent cell. The different therapeutic applications include melanoma, lung cancer, blood cancer, renal cell carcinoma, prostate cancer, bladder cancer, and others and involve various sectors such as hospitals, clinics, ambulatory surgical centers, and cancer research institutes. The immuno-oncology drugs market research report is one of a series of new reports from The Business Research Company that provides immuno-oncology drugs market statistics, including industry global market size, regional shares, competitors with an immuno-oncology drugs market share, detailed immuno-oncology drugs market segments, market trends and opportunities, and any further data you may need to thrive in the immuno-oncology drugs industry. This immuno-oncology drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global immuno-oncology drugs market grew from $70.59 billion in 2022 to $81.46 billion in 2023 at a compound annual growth rate (CAGR) of 15.4%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The immuno-oncology drugs market is expected to grow from $136.15 billion in 2027 at a CAGR of 13.7%. The rise in the number of cancer cases across the globe is likely to contribute to the growth of the immuno-oncology drug market. For instance, in January 2022, according to the American Cancer Society, there will likely be 1.9 million new cancer diagnoses and 609,360 cancer-related deaths in the US, or roughly 1,670 fatalities every day. The four most common types of cancer worldwide are lung, prostate, bowel, and female breast cancer, accounting for 43 percent of all new cancer cases. The four most common types of cancer worldwide are lung, prostate, bowel, and female breast cancer, accounting for 43% of new cancer cases. Therefore, the rise in cancer incidence rates globally is anticipated to boost demand for the immune-oncology drugs market over the coming years. The high cost of immuno-oncology therapies is a key factor hampering the growth of the market. The immunotherapy drugs cost more than other cancer drugs, and people who need immunotherapy for cancer, are often not able to afford it. High costs associated with drugs are a major issue faced by patients across the globe. The pressure to contain costs and demonstrate value is widespread. In less wealthy countries, the lack of cost-effective drugs has influenced the health conditions of the population and led to a low average life expectancy. Immunotherapy often costs an average annual price of more than $100,000 per patient, and if the value of medical assistance is included, the price would reach $850,000 per patient. Therefore, the high cost of immuno-oncology therapies is expected to hinder the growth of the immuno-oncology drug market. Companies in the immuno-oncology drug market are increasing their product innovation through strategic collaborations. To sustain themselves in the increasingly competitive immuno-oncology drug market, companies are developing innovative products as well as sharing skills and expertise with other companies. While companies have long collaborated with academic and research institutions in this market by way of partnerships and in- or out-licensing deals, this trend has been increasing over the past few years. For instance, in September 2020, AbbVie, Inc., a US based biopharmaceutical company specialising in drug discovery, research, and development, announced its research collaboration with I-Mab Biopharma Co. Ltd., a China based biopharmaceutical company pioneering in the discovery, development, and commercialization of biological drugs for immunology. Through this collaboration, both companies focus on the development of Lemzoparlimab (also known as TJC4), a cutting-edge anti-CD47 monoclonal antibody that I-Mab internally discovered and developed for the treatment of various cancers. The agreement covers its development and commercialization. The two partners may also decide to collaborate on further breakthrough cures in the future. In December 2021, Sanofi S.A., a France-based biopharmaceutical and healthcare company, acquired Amunix Pharmaceuticals, Inc., for an amount of $1 billion. Through this acquisition, Sanofi increases its capabilities in the development of innovative medicines for cancer patients, in research and drug discovery of immune-oncology therapeutic candidates, brings these potentially superior and safer treatment candidates to patients by utilising its expertise and working as a centre of excellence together, and increases its oncology pipeline. Amunix Pharmaceuticals, Inc., is a US-based biopharmaceutical company specialising in the discovery and development of novel immuno-oncology drugs. Major players in the immuno-oncology drugs market are Amgen Inc., AstraZeneca PLC., Bristol-Myers Squibb, Celgene Corporation, Eli Lilly and Company, Merck & Co., F. Hoffmann-La Roche AG, Johnson & Johnson, Novartis International AG, and AbbVie Inc. North America was the largest region in the immuno-oncology drugs market in 2022. The regions covered in the global immuno-oncology drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the immuno-oncology drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The immune-oncology drug market consists of sales of bevacizumab, alectinib, ibrutinib, imatinib, and palbociclib. Values in this market are "factory gate values," that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products. The global immuno-oncology drugs market is segmented - 1) By Type: Monoclonal Antibodies, Immune Checkpoint Inhibitors, Immune System Modulators, Cancer Vaccines, Other Types 2) By Therapeutic Application: Melanoma, Lung Cancer, Blood Cancer, Renal Cell Carcinoma, Prostate Cancer, Bladder Cancer, Other Therapeutic Applications 3) By End-User: Hospitals, Clinics, Ambulatory Surgical Centers, Cancer Research Institutes

Next generation sequencing (NGS) is a process used to determine the sequence of nucleotides in a section of DNA and is used in oncology research. NGS is used to identify rare cancer mutations and familial cancer mutation carriers and to provide molecular rationale for appropriate targeted therapy. The main technologies in clinical oncology next-generation sequencing are ion semiconductor sequencing, pyro-sequencing, synthesis sequencing, real-time sequencing, ligation sequencing, reversible dye termination sequencing, and nanopore sequencing. Ion semiconductor sequencing is a technique of DNA sequencing found on the observation of hydrogen ions that are released throughout the polymerization of DNA. The clinical oncology next-generation sequencing is used in various applications such as screening, companion diagnostics, and other diagnostics that are used by various end-users such as hospital laboratories, clinical research organizations, and diagnostic laboratories. The clinical oncology next-generation sequencing market research report is one of a series of new reports from The Business Research Company that provides clinical oncology next-generation sequencing market statistics, including clinical oncology next-generation sequencing industry global market size, regional shares, competitors with a clinical oncology next-generation sequencing market share, detailed clinical oncology next-generation sequencing market segments, market trends and opportunities, and any further data you may need to thrive in the clinical oncology next-generation sequencing industry. This clinical oncology next-generation sequencing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global clinical oncology next generation sequencing market grew from $0.39 billion in 2022 to $0.45 billion in 2023 at a compound annual growth rate (CAGR) of 14.7%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The clinical oncology next generation sequencing market is expected to grow from $0.75 billion in 2027 at a CAGR of 13.7%. The rise in the number of cancer cases across the globe is likely to contribute to the growth of the clinical oncology next-generation sequencing market during the forecast period. According to the American Cancer Society, there were 1.9 million new cases and 0.6 million cancer deaths in 2021 in the USA. The four most common types of cancer worldwide are lung, prostate, bowel, and female breast cancer, accounting for 43% of all the new cancer cases. Therefore, the rise in cancer incidence rate globally is anticipated to boost the demand for the clinical oncology next-generation sequencing market. High costs associated with the clinical oncology next-generation sequencing are a major issue faced by patients across the globe. The pressure to contain costs and demonstrate value is widespread. Political uncertainty and persistent economic stress in numerous countries are calling into question the sustainability of public health care funding. In low-income countries, the lack of cost-effective therapies for cancer has influenced the health conditions of the population and has led to a low average life expectancy. According to an article published in 2020 by Genetics in Medicine, the genome sequencing costs per cancer case is around £6,841, and costs per rare disease are around £7,050, and this cost is due to consumables that are the most expensive components in the sequencing process, and the equipment cost for rare cancer disease is higher when compared with normal cancer equipment, thus restraining the growth of the market. Companies in the clinical oncology next-generation sequencing are increasingly investing in automation of workflow to increase precision and reduce the sample-to-sample variability. For instance, Agilent automation solutions have developed an automation system that allows increasing the number of reactions that can perform in parallel, reducing the amount of sample processing time, and increasing the number of samples which can be processed while reducing the variability amount from sample to sample. Companies such as Sophia Genetics are also investing in data-driven medicine that looks into automating DNA sequencing to better diagnose and treat patients. In April 2021, Agilent Technologies, a US-based life sciences technology company, acquired Resolution Bioscience for an undisclosed amount. The acquisition would expand Agilent's capabilities in the fields of next-generation sequencing for cancer diagnostics. Resolution Bioscience is a US-based developer of next-generation sequencing (NGS)-based precision oncology solutions. Major players in the clinical oncology next-generation sequencing market are Thermo Fisher Scientific (Qiagen), Oxford Nanopore Technologies, QIAGEN, Myriad Genetics, Illumina, F. Hoffmann-La Roche, Perkin Elmer, Agilent Technologies, Pacific Bioscience, and Caris Life Sciences. North America was the largest region in the clinical oncology next-generation sequencing market in 2022. Asia-Pacific was the second largest region in the global clinical oncology next-generation sequencing market. The regions covered in the global clinical oncology next-generation sequencing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the clinical oncology next-generation sequencing market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The clinical oncology next-generation sequencing market consists of sales of genetic sequencing equipment with advanced features and technologies such as ion semiconductors sequencing, pyro-sequencing, synthesis sequencing (SBS), real-time sequencing (SMRT), ligation sequencing, and other techniques that are used in oncology research for determining the nucleotide sequence leading to clinical oncology. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global clinical oncology next generation sequencing market is segmented - 1) By Technology: Ion Semiconductor Sequencing, Pyro-Sequencing, Synthesis Sequencing, Real Time Sequencing, Ligation Sequencing, Reversible Dye Termination Sequencing, Nano-Pore Sequencing 2) By Application: Screening, Companion Diagnostics, Other Diagnostics 3) By End User: Hospital Laboratories, Clinical Research Organizations, Diagnostic laboratories

Interventional oncology devices are used in the diagnosis and treatment of cancer using minimally invasive techniques and advanced imaging technology. The main products of interventional oncology devices are embolization devices, ablation devices, and support devices. The embolization devices are intended for the embolization of the blood vessels of a variety of tumors. The interventional oncology devices are used to perform procedures such as thermal tumour ablation, non-thermal tumour ablation, transcatheter arterial chemoembolization (TACE), transcatheter arterial radioembolization (TARE), or selective internal radiation therapy (SIRT), and transcatheter arterial embolization (TAE), or bland embolization, that are used to treat cancer types such as liver cancer, kidney cancer, lung cancer, bone cancer, and others. The interventional oncology devices market research report is one of a series of new reports from The Business Research Company that provides interventional oncology devices market statistics, including interventional oncology devices industry global market size, regional shares, competitors with a interventional oncology devices market share, detailed interventional oncology devices market segments, market trends and opportunities, and any further data you may need to thrive in the interventional oncology devices industry. This interventional oncology devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global interventional oncology devices market size will grow from $2.21 billion in 2022 to $2.35 billion in 2023 at a compound annual growth rate (CAGR) of 6.4%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The interventional oncology devices market size is expected to grow from $3.03 billion in 2027 at a CAGR of 6.5%. The availability of private and government funding drove the interventional oncology devices market. In the field of cancer, funding from the government and private has increased, especially for the devices used in treatments as it promotes early detection and better survival rates. The American Cancer Society, the largest non-government, not-for-profit cancer research funder, has awarded 630 projects with a grant amount of $384,262,652 in 2021. BioProtect Ltd., an Israeli company that develops novel bioabsorbable polymer spacer balloons, received a funding of $13 million of its Series D equity financing from a leading global syndicate of venture investors that finances the ongoing multicenter FDA clinical trial of BioProtect's lead product, the ProSpace balloon spacer, which protects prostate cancer patients undergoing radiation therapy. Endosight, the first augmented-reality-guided ablative system, has received 20% of its funding from private organizations. The funding from government and private organizations helps in the development of new technologies and devices, thereby driving the interventional oncology devices market. Rising product recalls are likely to hinder the demand for interventional oncology devices. The number of interventional oncology product recalls has risen. For instance, in June 2020, the IceFORCE 2.1 CX Prostate Cryoablation Kit Visual ICE System of the Boston Scientific Corporation was recalled as the needle surface had deteriorated. In March 2020, Medtronic recalled the Pipeline Flex embolization system with Shield technology due to a fracture in the distal portion. These product recalls put financial strain on businesses and also hampers the demand, thus hindering the market. Companies are focusing on deploying robotics technology in interventional oncology devices, for higher efficiency. The robotic system integrates image-based planning and navigation with the installation of different instruments to the desired body part with better accuracy and efficiency. For instance, in March 2022, the U.S. Food and Drug Administration approved Quantum Surgical’s Epione interventional oncology robotics platform. In July 2020, Terumo Corporation, a Japanese medical device company, acquired Quirem Medical for $45 million. Through this acquisition, Terumo intends to launch the Holmium platform globally as a part of the ongoing expansion of its interventional oncology (IO) portfolio. It further strengthens the brand and extends manufacturing and clinical development activities. Quirem Medical is a Netherlands-based medical device company that develops and markets Holmium-166-based radioactive microspheres for Selective Internal Radiation Therapy (SIRT). Major players in the interventional oncology devices market are Boston Scientific Corporation, Medtronic PLC., Terumo Corporation, Merit Medical Systems Inc., Philips Volcano, AngioDynamics Inc., GE Healthcare, Siemens Healthineers, Sirtex Medical, and Cook Medical Incorporated. North America was the largest region in the interventional oncology devices market in 2022. Asia-Pacific was the second largest region in the global interventional oncology devices market report. The regions covered in the global interventional oncology devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the interventional oncology devices market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The interventional oncology devices market consists of sales of embolization devices, ablation devices, and support devices. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global interventional oncology devices market is segmented - 1) By Product: Embolization Devices, Ablation Devices, Support Devices 2) By Procedure: Thermal Tumor Ablation, Non-thermal Tumor Ablation, Transcatheter Arterial Chemoembolization (TACE), Transcatheter Arterial Radioembolization (TARE) or Selective Internal Radiation Therapy (SIRT), Transcatheter Arterial Embolization (TAE) or Bland Embolization 3) By Cancer Type: Liver Cancer, Kidney Cancer, Lung Cancer, Bone Cancer, Other Cancer Types

Oncology devices are medical devices used in the diagnosis, management, and treatment of cancer. The main device types of oncology devices are brachytherapy devices and endoscopic devices. Endoscopic devices are medical devices used in the diagnosis, management, and treatment of cancer. It is used to look internally at a body cavity or organ. These are used in various therapies such as chemotherapy, hormone therapy, biotherapy/immunotherapy, and radiation therapy that are used by various end-users such as hospitals, cancer research institutes, and others. The oncology devices market research report is one of a series of new reports from The Business Research Company that provides oncology devices market statistics, including oncology devices industry global market size, regional shares, competitors with a oncology devices market share, detailed oncology devices market segments, market trends and opportunities, and any further data you may need to thrive in the oncology devices industry. This oncology devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global oncology devices market grew from $107.81 billion in 2022 to $128.33 billion in 2023 at a compound annual growth rate (CAGR) of 19.0%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The oncology devices market is expected to grow from $250.74 billion in 2027 at a CAGR of 18.2%. A growing number of cancer cases across the globe is anticipated to boost the demand for the oncology devices market. Cancer is a major health problem across the globe and is the second leading cause of death in the USA. The increasing incidence of cancer is contributing to the surge in demand for oncology devices to treat cancer patients. The four most common types of cancer globally are prostate, lung, bowel, and female breast cancer, accounting for 43% of all new cancer cases. According to the American Cancer Society, there were 1.9 million new cases and 608,570 cancer deaths in 2021 in the USA. Therefore, the rise in cancer incidence is anticipated to boost the demand for the oncology drugs market. The low per capita expenditure on healthcare in developing countries is anticipated to limit the growth of the oncology devices market. The per capita expenditure on healthcare is very low in emerging economies such as China, India, and Indonesia as compared to developed nations. For instance, in 2020, according to India's total per capita, government spending on healthcare has almost doubled from ?1,008 per person in the year 15 to ?1,944 in the year 2020 but is still low. The total expenditure by the Centre and states for the year 2020 was ?2.6 trillion, or 1.29% of GDP, as well as establishment expenditure comprising salaries, gross budgetary help to different institutions and hospitals, and transfers to states centrally sponsored schemes like Ayushman Bharat. Major companies in the market, research institutes, and governments are continuously focusing on developing new devices to treat cancer patients. For instance, AIROS Medical Inc., a medical technology company based in the USA, launched AIROS 6 sequential compression therapy device and garment system to treat breast cancer patients. The advanced technology expanded upper extremity post-mastectomy treatment options for patients with lymphedema. In May 2021, GE Healthcare, a US-based manufacturer of medical devices, acquired Zionexa for an undisclosed amount. The acquisition would help GE healthcare to develop more personalised treatments for cancer. Zionexa is a French developer of cancer and neurology biomarkers. Major players in the oncology devices market are Eckert & Ziegler BEBIG, Oncura Inc., GE Healthcare, Medtronic PLC., Varian Medical Systems Inc., Elekta AB, Theragenics Corporation, Accuray Incorporated, Roche Diagnostics, and IBA Group. North America was the largest region in the oncology devices market in 2022. Asia-Pacific was the second largest region in the global oncology devices market report. The regions covered in the global oncology devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the oncology devices market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The oncology devices market consists of sales of brachytherapy devices and endoscopic devices. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products. The global oncology devices market is segmented - 1) By Device Type: Brachytherapy Devices, Endoscopic Devices 2) By Therapy: Chemotherapy, Hormone Therapy, Biotherapy/Immunotherapy, Radiation Therapy 3) By End User: Hospitals, Cancer Research Institutes, Other End Users

Oncology nutrition refers to eating a healthy and balanced diet prescribed for a cancer patient. Eating the right kinds of food before, during, and after treatment can help patients feel better and stay stronger. Oncology nutrition is used to improve clinical outcomes in certain cancer types. The main types of cancer in oncology nutrition are blood cancer, breast cancer, stomach and gastrointestinal cancers, liver cancer, pancreatic cancer, and others. Stomach and gastrointestinal cancers refer to cancers that are caused in any part of the stomach. The different types of nutrition include enteral nutrition and parenteral nutrition and are employed in hospitals, homecare, specialty clinics, and other end users. The oncology nutrition market research report is one of a series of new reports from The Business Research Company that provides oncology nutrition market statistics, including oncology nutrition industry global market size, regional shares, competitors with an oncology nutrition market share, detailed oncology nutrition market segments, market trends and opportunities, and any further data you may need to thrive in the oncology nutrition industry. This oncology nutrition market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry. The global oncology nutrition market size grew from $1.52 billion in 2022 to $1.69 billion in 2023 at a compound annual growth rate (CAGR) of 11.2%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The oncology nutrition market size is expected to grow to $2.39 billion in 2027 at a CAGR of 9.1%. An increase in the prevalence of cancer is significantly contributing to the growth of the oncology nutrition market going forward. Cancer incidence refers to the number of new cancer cases arising in a specified population over a given period of time. People suffering from cancer require adequate food with sufficient nutrition. As a result, the rise in the incidence of cancer increases the demand for oncology nutrition. For instance, in 2020, according to the World Health Organization, a Switzerland-based health agency, 19.3 million new cancer cases were registered, and almost 10.0 million cancer deaths occurred in the US. Therefore, the rising incidence of cancer will contribute to the growth of the oncology nutrition market. Strategic partnerships have emerged as a key trend gaining popularity in the oncology nutrition market. Organizations operating in oncology nutrition are focused on strategic partnerships to meet consumer demand and reinforce their position. For instance, in October 2021, NIHR Cancer and Nutrition, a UK-based cancer organization, collaborated with the World Cancer Research Fund, a UK-based non-profit association. This partnership focuses on training and delivering consistent information on nutrition to cancer patients. Furthermore, in March 2022, Hope Connections, a US-based non-profit organization, collaborated with Food & Friends, a US-based oncology nutrition organization, to help with nutrition awareness in oncology. In March 2021, Nature’s Way, a US-based supplement company, acquired Baze for an undisclosed amount. The acquisition would bring together the expertise of both the companies to deliver innovative solutions to the patients. Baze is a US-based personalized nutrition company that provides nutrition according to the needs of patients and normal people. Major players in the oncology nutrition market are B. Braun Melsungen AG, Danone India, Abbott Laboratories, Nestle S.A., Victus, Hormel Food Corporation, Meiji Holdings, Pfizer Inc., Baxter International, Mead Johnson Nutrition Company, Fresenius Kabi AG, Braun Melsungen AG, Auris Health Inc., Aceto, and Hansen Medical. North America was the largest region in the oncology nutrition market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the oncology nutrition market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the oncology nutrition market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.   The oncology nutrition market includes revenues earned by entities by bladder cancer, breast cancer, colorectal cancer, kidney cancer, and lung cancer. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global oncology nutrition market is segmented - 1) By Cancer Type: Blood Cancer, Breast Cancer, Stomach and Gastrointestinal Cancers, Liver Cancer, Pancreatic Cancer, Other Cancer Types 2) By Nutrition: Enteral Nutrition, Parenteral Nutrition 3) By End-Users: Hospitals, Homecare, Specialty Clinics, Other End Users

The oncology drugs market consists of sales of oncology drugs and related services by entities (organizations, sole traders and partnerships) that produce oncology drugs to diagnose and treat all types of cancers. This industry includes establishments that produce drugs used in chemotherapy, surgery and radio therapies for treating pancreatic cancer, breast cancer, ovarian cancer, brain tumor, and other different cancer types. The main types of oncology drugs are lung cancer drugs, pancreatic cancer drugs, breast cancer drugs, prostate cancer drugs, ovarian cancer drugs, colorectal cancer drugs, gastric cancer drugs, kidney cancer drugs, brain tumor drugs, thyroid cancer drugs, skin cancer drugs, bladder cancer drugs, cervical cancer drugs, blood cancer drugs and others (kaposi sarcoma, aids-related lymphoma, anal cancer, bone cancer, retinoblastoma, testicular cancer, hepatocellular (liver) cancer, mouth cancer, neuroblastoma). Breast cancer drugs are used to target and destroy breast cancer cells. The drugs are administered through oral, parenteral, and others that are classified into branded and generic drugs. The various mode of purchase includes prescription-based drugs and over-the-counter drugs which are distributed by hospital pharmacies, retail pharmacies/ drug stores and others. The global oncology drugs market size is expected to grow from $199.95 billion in 2021 to $223.21 billion in 2022 at a compound annual growth rate (CAGR) of 11.6%. The growth in the market is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The oncology drugs market is expected to reach $540.60 billion in 2026 at a CAGR of 24.8%. The outbreak of the Coronavirus disease (COVID-19) has acted as a significant restraint on the oncology drugs market in 2020 as supply chains were disrupted due to restrictions on trade of pharmaceutical ingredients and products across countries. COVID-19 is an infectious disease with flu-like symptoms including fever, cough, and difficulty in breathing. The virus was first identified in 2019 in Wuhan, Hubei province of the People’s Republic of China and spread globally including Western Europe, North America and Asia. Steps by national governments to contain the transmission have resulted in a decline in economic activity with countries entering a state of lockdown and the outbreak had a negative impact on businesses throughout 2020 and into 2021. Pharmaceutical markets such as this one has been relatively unaffected however due to continued availability of drugs during government lock downs and inelasticity of demand. It is expected that the oncology market will recover from the shock across the forecast period as it is a 'black swan' event and not related to ongoing or fundamental weaknesses in the market or the global economy. Companies in the oncology drugs market are increasingly investing in technologies such as artificial intelligence (AI) to save time and reduce research and development costs. AI is the simulation of human intelligence processes by machines, especially computer systems, which has the potential to surpass human intelligence levels. This technology helps to analyze large sets of chemical and biological data to identify potential drug candidates with higher success rates and at a quicker pace when compared to human analysis. The technology also helps in speeding up the patient recruitment process by matching cancer patients with the most relevant clinical trials, thus lowering clinical trial costs. Major oncology drug manufacturers such as Roche, Pfizer and Johnson and Johnson have already invested in AI technologies to reduce time taken and costs incurred for drug development. For example, Johnson and Johnson has recently entered into an agreement with BenevolentAI, a UK-based start-up, to mine data for designing new oncology drugs. Companies in the oncology drug market are investing in targeted therapy, which has proven to be less toxic compared to traditional treatment options. Targeted cancer therapies are drugs or substances which block the growth of cancer by interfering with molecules that are more specifically involved in cancer cell progression than in normal cell activity. The goal of these therapies is to eliminate cancerous cells in the body while leaving normal cells unharmed. By focusing on changes in the cell that are specific to cancer, this therapy may prove to be more effective than traditional chemotherapy and radiotherapy. Companies in oncology market such as Pfizer, Novartis and Abbvie have understood the importance of this treatment method and are increasingly investing in it. According to a report by QuintilesIMS, 87% of the drugs currently in pipeline constitute of targeted therapy drugs. Major companies in the oncology drugs market include F. Hoffmann-La Roche Ltd, Novartis AG, Gilead Sciences Inc, Bayer AG, and Takeda Pharmaceticals. North America was the largest region in the oncology drugs market in 2021. The Middle East is expected to be the fastest growing region in the forecast period The regions covered in the oncology drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the oncology drugs market report are Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa, South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela and Vietnam. The global oncology drugs market is segmented - 1) By Type: Lung Cancer Drugs, Pancreatic Cancer Drugs, Breast Cancer Drugs, Prostate Cancer Drugs, Ovarian Cancer Drugs, Colorectal Cancer Drugs, Gastric Cancer Drugs, Kidney Cancer Drugs, Brain Tumor Drugs, Thyroid Cancer Drugs, Skin Cancer Drugs, Bladder Cancer Drugs, Cervical Cancer Drugs, Blood Cancer Drugs, Others (Kaposi Sarcoma, AIDS-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicular Cancer, Hepatocellular (Liver) Cancer, Mouth Cancer, Neuroblastoma) 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies/ Drug Stores, Others 3) By Route of Administration: Oral, Parenteral, Others 4) By Drug Classification: Branded Drugs, Generic Drugs 5) By Mode of Purchase: Prescription-Based Drugs, Over-The-Counter Drugs